NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
22 Oktober 2024 - 3:00PM
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:
NRXS), a medical technology company commercializing neuromodulation
therapies addressing chronic and debilitating conditions in
children and adults, announced that the American Medical
Association (AMA) has established a new Current Procedural
Terminology (CPT) Category I code for Percutaneous Electrical Nerve
Field Stimulation (PENFS) procedures effective January 1, 2026.
NeurAxis’ PENFS technology, IB-Stim, is
FDA-cleared for functional abdominal pain associated with irritable
bowel syndrome (IBS) in adolescents 11-18 years old. IB-Stim is a
non-surgical device that sends gentle electrical impulses into
cranial nerve bundles in the ear. There are currently no
FDA-approved drug therapies for children with abdominal
pain-related disorders of the gut-brain interaction. Pharmacologic
treatments which use drugs off-label can often have serious side
effects, and most lack scientific evidence of efficacy.
“This is a wonderful day for children and
adolescents suffering from IBS. The availability of a Category I
code recognizes the strong clinical evidence and utilization of
PENFS procedures, led by IB-Stim. Obtaining a Category I code for
this important technology is a key milestone for our initiatives to
drive patient awareness of FDA cleared options for IBS and access
for PENFS treatment,” said Brian Carrico, President and Chief
Executive Officer of NeurAxis.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company
focused on neuromodulation therapies to address chronic and
debilitating conditions in children and adults. NeurAxis is
dedicated to advancing science and leveraging evidence-based
medicine to drive the adoption of its IB-Stim™ therapy, which is
its proprietary Percutaneous Electrical Nerve Field Stimulation
(PENFS) technology, by the medical, scientific, and patient
communities. IB-Stim™ is FDA-cleared for functional abdominal pain
associated with irritable bowel syndrome (IBS) in adolescents 11-18
years old. Additional clinical trials of PENFS in multiple
pediatric and adult conditions with large unmet healthcare needs
are underway. For more information, please visit
http://neuraxis.com.
This page discusses ongoing activities
concerning percutaneous electrical nerve field stimulator (PENFS)
technology. For details on instructions for use, precautions,
warnings and important information, see
https://ibstim.com/important-information/.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements other than statements of
historical fact are forward-looking statements. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results and other events may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. There are a number of important factors
that could cause actual results, developments, business decisions
or other events to differ materially from those contemplated by the
forward-looking statements in this press release. These factors
include, among other things, the conditions in the U.S. and global
economy, the trading price and volatility of the Company’s stock,
public health issues or other events, the Company’s compliance with
applicable laws, the results of the Company’s clinical trials and
perceptions thereof, the results of submissions to the FDA, the
results of the shareholder vote to enable the issuance of the
Preferred Stock, and factors described in the Risk Factors section
of NeurAxis’s public filings with the Securities and Exchange
Commission (SEC). Because forward-looking statements are inherently
subject to risks and uncertainties, you should not rely on these
forward-looking statements as predictions of future events. These
forward-looking statements speak only as of the date of this press
release and, except to the extent required by applicable law, the
Company undertakes no obligation to update or revise these
statements, whether as a result of any new information, future
events and developments or otherwise.
Contacts
CompanyNeurAxis,
Inc.info@neuraxis.com
Investor RelationsLytham PartnersBen
Shamsian646-829-9701shamsian@lythampartners.com
Neuraxis (AMEX:NRXS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Neuraxis (AMEX:NRXS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024